Research Expert: Sarah Overall
  • Published: Feb 2025
  • Pages: 150
  • SKU: IRTNTR80288

  • Ophthalmoplegia Market: Growth Trends, Segmentation, and Key Players (2024-2028)

    The Gobal ophthalmoplegia market is projected to grow by USD 435.8 million from 2024 to 2028, at a CAGR of 6%. Ophthalmoplegia is a neurological disorder that affects eye muscle movement, leading to double vision, blurred vision, and muscle weakness. It can be congenital or associated with systemic conditions such as multiple sclerosis and other neurological diseases.Market growth is driven by the increasing prevalence of neurological disorders, the aging population, and the limited treatment options currently available. While advancements in diagnostic tools and medical treatments continue to improve patient care, the market still presents opportunities for innovation in effective and accessible therapies

    Global Ophthalmoplegia Market 2024-2028

    For more details about the industry, get the PDF sample report for free

    Market Segmentation

    The ophthalmoplegia market is segmented by end-user, product type, and geography.

    By End-User

    • Hospitals
    • Clinics
    • Ambulatory Clinics

    By Product Type

    • Pharmaceuticals
    • Medical Devices

    By Geography

    • North America
      • US
      • Canada
    • Europe
      • Germany
      • UK
      • France
      • Italy
    • Asia
      • India
      • Japan
    • Rest of World (ROW)

    Key Market Insights

    End-User Insights

    The hospitals segment is expected to experience substantial growth as hospitals remain the primary diagnostic and treatment centers for eye movement disorders. Large tertiary care centers and academic medical institutions are equipped with specialized ophthalmology departments and advanced diagnostic tools.

    • In 2018, the hospitals segment was valued at USD 723.60 million.
    • Hospitals offer multidisciplinary care, including neurologists, ophthalmologists, and rehabilitation services.
    • Treatment options include medications, botulinum toxin injections, surgical procedures, and prism glasses.

    Market Growth Drivers

    1. Growing Geriatric Population

    • By 2030, one in six people worldwide will be aged 60 or older.
    • The aging population is expected to reach 1.4 billion by 2030 and 2.1 billion by 2050.
    • The 80+ age group is projected to triple to 426 million by 2050.
    • Older individuals are more susceptible to neurological disorders, such as internuclear ophthalmoplegia and inferior rectus muscle dysfunction.

    2. Rising Neurological Disorders

    • Neurological diseases, including multiple sclerosis, stroke, brain tumors, migraines, and mitochondrial disorders, are increasing.
    • According to the WHO (2021), over 3 billion people globally suffer from neurological conditions.
    • As these disorders contribute to ophthalmoplegia, demand for medical devices and treatments continues to grow.

    Market Challenges

    1. Limited Treatment Options

    • Current therapies include corticosteroids, immunosuppressants, and surgery, but they are not always effective.
    • Patients with rare forms of ophthalmoplegia or those unresponsive to standard treatments have limited options.
    • Unmet medical needs drive R&D efforts in gene therapy and stem cell treatments.

    Get more details by ordering the complete report

    Key Companies in the Ophthalmoplegia Market

    Some of the key companies of the Ophthalmoplegia Market are as follows:

    • AbbVie Inc.
    • Agnitio Pharma
    • Atom Pharma
    • Care Formulation Labs Pvt Ltd
    • Cellera Farma
    • Deutsche Pharma Laboratories
    • FarmaSyn SA
    • GlaxoSmithKline Plc
    • Innovative Pharmaceuticals Pvt Ltd
    • Medytox
    • Merz Pharma GmbH and Co KGaA
    • Novartis AG
    • Orchidia Pharmaceutical Industries
    • Pfizer Inc.
    • Sally Pharmacies
    • Symbiotec Pharmalab Pvt. Ltd

     

    Read News Read Less
    Interested in this report?
    Get your sample now!

Safe and Secure SSL Encrypted

Technavio

  • 2500 USD

[5 reports/month/user]

  • 5000 USD

close
  • Basic Plan [5000 USD/Year]:

    Single User
    Download 5 Reports/Month
    View 100 Reports/Month
    Add upto 3 Users at 625 USD/user

  • Teams Plan [7500 USD/Year]:

    5 User
    Download 5 Reports/Month/User
    View 100 Reports/Month/User
    Add upto 30 Users at 500 USD/user

*You can upgrade to Teams plan at Subscription page

close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization).
    Complimentary Customization Included

*For Enterprise license, go to checkout page

Technavio Get the report (PDF) sent to your email within minutes.